BioSpace News Archive

Global Blood Therapeutics, Inc. announced that on August 1, 2019, the compensation committee of GBT’s board of directors granted 14 new employees options to purchase an aggregate of 26,200 shares of the company’s common stock with a per share exercise price of $54.25 and restricted stock units for an aggregate of 69,450 shares of the company’s common stock.

Revelations could personalise treatment, including picking out those likely to benefit from immunotherapy

Quantum Genomics are the creators of Firibastat, a first-in-class brain aminopeptidase inhibitor that could potentially treat treatment-resistant hypertension by acting in the brain to interfere with the renin-angiotensin system.

The two posters outlining ongoing formulation efforts to develop a trivalent thermostabilized Ebola vaccine presented on Wednesday July 31 at the 2019 Colorado Protein Stability Conference are now available.

Device Also Can Serve as Robotic Skin, Relaying Information Back to the User

Pratteln, Switzerland, August 2, 2019 – Santhera Pharmaceuticals announces the closing of the licensing transaction with Chiesi Farmaceutici, an international research-focused healthcare group.

Loan reduced from US$30 million to US$11.5 million

The next level of analytical intelligence in FE-SEM for combining high resolution and operability

AACC released a position statement calling for increased collaboration between clinical laboratories, the healthcare community, and federal agencies to end the opioid epidemic.

VUCA Health announced that it has partnered with Allen Technologies, an interactive patient engagement solutions provider, to deliver its MedsOnCue video content through Allen’s E3 patient engagement solution to health systems across the country.